一次情報の記録
この四半期更新では、palazestrantの第3相OPERA-01試験が2027年第1四半期にトップライン結果を報告する予定であることが再確認されています。また、palazestrantとribociclibを併用した第3相OPERA-02試験の登録が引き続き順調であることも記載されています。
EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Reports Third Quarter 2026 Financial and Operating Results • On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 • Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136 • Appointed Jason O’Byrne, MBA, as Chief Financial Officer • Ended the third quarter with $413.8 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, November 10, 2026 (Globe NewsWire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported